Business Wire

TX-MARY-KAY

Share
Mary Kay Reveals Research on Skin Barrier Function and Facial Redness at the Chinese Association of Integrative Medicine Meeting

As one of the world’s leading skincare innovators in the direct selling and cosmetic industries, Mary Kay continued its decades-long commitment to skin science research by revealing the results of a study to improve skin barrier function and facial redness at the Annual Meeting of the Dermatology Committee organized by the Chinese Association of Integrative Medicine. Mary Kay was also a sponsor of the event, which took place August 8-11 in Lanzhou, Gansu Province, China.

“Mary Kay scientists spend years doing skin research to develop solutions for real people, and real needs,” said Dr. Lucy Gildea, Chief Scientific Officer at Mary Kay Inc. “Part of our commitment is to take an active role in the beauty and scientific communities through our participation in global dermatological conferences, where we can share and learn from other scientific experts to help us develop more effective and innovative products.”

Mary Kay China’s Sr. Manager for Medical Affairs, Dr. Jenny Jiang, shared research results of strategies to improve the skin barrier function and facial redness. These findings may provide important insights to understanding sensitive skin. Attendees included the country’s top dermatologists and esteemed executives from cosmetic companies.

Mary Kay’s Research and Development team is comprised of distinguished scientists who hold doctorates and other advanced degrees across multiple disciplines: skin biology, cell biology, chemistry, biochemistry and more. The team is dedicated to conducting ongoing breakthrough research and sharing impactful findings related to skin health with the scientific and beauty communities at large.

Every year, Mary Kay conducts hundreds of thousands of scientific tests on products and ingredients to ensure the highest standards of safety, quality, and performance. Mary Kay holds more than 1,500 patents for products, technologies, and packaging designs in its global portfolio. Last year, the company opened a more than $100 million state-of-the-art manufacturing and R&D facility in Lewisville, Texas.

About Mary Kay

One of the original glass ceiling breakers, Mary Kay Ash founded her beauty company more than 55 years ago with three goals: offer rewarding opportunities for women, provide irresistible products and make the world a better place. That dream has blossomed into a multibillion-dollar company with millions of independent sales force members in nearly 40 countries. Mary Kay is dedicated to researching the science behind beauty and to manufacturing cutting-edge skin care, color cosmetics, fragrances and nutritional supplements. Through The Mary Kay FoundationSM , the company has awarded more than $78 million to cancer research and domestic violence shelters. Mary Kay Ash’s original vision continues to shine—one lipstick at a time.

Social Media:

https://www.facebook.com/marykayglobal/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Meiji Seika Pharma Partners With MBC BioLabs to Strengthen Global Innovation in Drug Discovery19.12.2025 02:00:00 CET | Press release

Meiji Seika Pharma Co., Ltd. (Headquarters: Chuo-ku, Tokyo; President & CEO: Toshiaki Nagasato) today announced that it has entered into a partnership agreement with MBC BioLabs which is a private organization supporting the development of biotech startup companies in California’s San Francisco Bay Area. MBC BioLabs provides fully equipped research facilities and a supportive community that help biotech entrepreneurs accelerate from concept to company. By removing the burden of building and maintaining laboratory infrastructure, resident companies can focus early on research and development while efficiently advancing commercialization. Through this partnership, Meiji Seika Pharma will further advance its open-innovation initiatives and strengthen research and development in its priority therapeutic areas: infectious diseases, hematologic diseases, and immune-inflammatory diseases. By engaging with the entrepreneurs and startup community at MBC BioLabs, the company aims to discover inn

Enry's Island SpA Strengthens Its Leadership in Venture Capital with Explosive Growth and Redesigns the Future of VC Through Gaming19.12.2025 00:34:00 CET | Press release

Announcement of Enry’s Island AdVentures: the world’s first video game to learn how to launch and scale startups, focused on democratizing innovation for “Long Tail Users” Enry’s Island SpA (WBAG:EIOS), the world’s first publicly listed venture builder, announces a new era of growth, innovation, and the democratization of Venture Capital (VC). The company has delivered exceptional results, consolidating its position as an industry leader through a strategic positioning in the rapidly expanding gaming market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251218742236/en/ Record Growth and Performance Enry’s Island SpA has demonstrated an extraordinary growth trajectory and a strong financial and operational track record: Revenues: +250% year-over-year (YoY). Exit: $3.6M in exits realized via IPO. Portfolio: 1 IPO of a portfolio company completed in December 2024, with an additional 2 IPOs expected in 2026. The performance of

500 Global Expands Africa Presence; Selected to Advance Digital Morocco 2030 Strategy18.12.2025 21:37:00 CET | Press release

Part of the Digital Morocco 2030 strategy, 500 Global has been selected to support the Startup Venture Building (Startup VB) initiative. 500 Global, one of the world’s most active venture capital firms1, announced it has been selected to support the Ministry-led Startup VB initiative, a flagship program under the Digital Morocco 2030 strategy2. This announcement marks a significant milestone in 500 Global’s continued expansion across the African continent and its work collaborating with governments to strengthen national innovation ecosystems. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251218363323/en/ Announcement of 500 Global's continued expansion across Africa and support of Digital Morocco 2030 Launched by the Ministry of Digital Transition and Administrative Reform (Ministry) and deployed by TAMWILCOM, the Startup VB initiative is a flagship program under the Digital Morocco 2030 strategy. Startup VB aims to streng

Neural Concept Closes $100M Funding Round Led by Growth Equity at Goldman Sachs Alternatives to Scale AI-Native Engineering18.12.2025 17:00:00 CET | Press release

New capital accelerates Neural Concept’s ability to deliver transformative technologies and enterprise-wide AI impact across advanced industrial workflows.Platform delivers CAD-native, physics-aware AI and deep reasoning for engineering, saving customers $50 million annually, reducing late-stage redesigns by 30-50% and accelerating time to market by up to two years.The company has generated a fourfold increase in enterprise revenue over the past 18 months.More than 50 global companies are actively relying on the platform, including General Motors, General Electric Vernova, Leonardo Aerospace, Eaton, Safran, Renault Group and multiple Formula 1 teams. Neural Concept, a global AI platform and leader in Engineering Intelligence powering next-generation product development, today announced it raised a $100 million Series C funding round led by Growth Equity at Goldman Sachs Alternatives, with existing investors Forestay Capital, Alven, HTGF, D.E. Shaw Ventures and Aster Capital. This press

Croma-Pharma Introduces New Medical Device for the Preparation of Autologous PRP | Fluid- PRF18.12.2025 16:57:00 CET | Press release

Croma-Pharma, a global player in minimally invasive aesthetic medicine, proudly announces the launch of its new medical device that is used for the preparation of autologous Platelet-Rich Plasma (PRP) | Fluid-Platelet-Rich Fibrin (Fluid-PRF).1 This launch represents continued progress in Croma’s mission to provide healthcare professionals state-of-the-art tools for their practice. With its innovative design and optimized separation technology, Exprecell™ enables the efficient preparation of autologous blood concentrates, without the use of anticoagulants, resulting in the formation of Fluid-PRF, a biologically active concentrate that retains the regenerative properties of platelets and leukocytes, yet stays liquid for a defined period.1 What makes Exprecell™ special?MDR certification: Exprecell™ is MDR-certified, meeting stringent EU regulatory requirements to ensure the safe, controlled and standardized preparation of autologous Platelet-Rich Plasma (PRP) | Fluid-Platelet-Rich Fibrin

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye